PHAXIAM Therapeutics S.A. (PHXM) — Cash Flow-to-Debt Ratio
PHAXIAM Therapeutics S.A. (PHXM) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2024, meaning its operating cash flow of €-8.34 Million could theoretically repay 0% of its total liabilities (€23.66 Million) in one year. See PHXM cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PHAXIAM Therapeutics S.A. Cash Flow-to-Debt Ratio (2012–2023)
Historical debt coverage capacity for PHAXIAM Therapeutics S.A. across 12 annual periods. Also explore PHAXIAM Therapeutics S.A. (PHXM) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for PHAXIAM Therapeutics S.A. (2012–2023)
Year-by-year debt coverage analysis for PHAXIAM Therapeutics S.A.. For market capitalisation and broader financial context, see PHAXIAM Therapeutics S.A. (PHXM) total market value.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.95x | €-24.43 Million | €25.70 Million | ▲ +33.7% |
| 2022 | -1.43x | €-31.99 Million | €22.32 Million | ▼ -10.1% |
| 2021 | -1.30x | €-57.14 Million | €43.92 Million | ▼ -34.6% |
| 2020 | -0.97x | €-52.05 Million | €53.86 Million | ▲ +26.7% |
| 2019 | -1.32x | €-43.51 Million | €32.99 Million | ▲ +25.3% |
| 2018 | -1.77x | €-39.27 Million | €22.24 Million | ▲ +1.0% |
| 2017 | -1.78x | €-24.70 Million | €13.84 Million | ▲ +5.6% |
| 2016 | -1.89x | €-17.64 Million | €9.33 Million | ▲ +23.8% |
| 2015 | -2.48x | €-14.58 Million | €5.87 Million | ▼ -64.0% |
| 2014 | -1.51x | €-7.24 Million | €4.78 Million | ▼ -2.0% |
| 2013 | -1.48x | €-6.47 Million | €4.36 Million | ▼ -3484.0% |
| 2012 | 0.04x | €621.40K | €14.17 Million | — |